Secukinumab, an anti-IL-17A monoclonal antibody, is commonly used for the treatment of psoriasis. The IL-17A cytokine has been linked to immune-mediated disorders, and in the FIXTURE study, secukinumab had proven superior to placebo and etanercept in treating psoriasis. Side effects of secukinumab could include neutropenia, susceptibility to candida (including chronic mucocutaneous candidiasis), superficial dermatophytosis, worsening of Crohn's disease, and increased likelihood of tuberculosis. In this report, we assess a patient who has suffered from psoriasis for 30 years, and incorrectly injected the drug daily, instead of weekly, for her first five doses. In just two weeks following the overdose, the patient's Physician's Global Assessment decreased from 4 to 2, and the patient was continued on the drug after one month. This case report represents the high safety index of secukinumab in 300 mg dosing.
KundakciN.TursenU.BabikerM.O.GurgeyE.. The evaluation of the sociodemographic and clinical features of Turkish psoriasis patients.Int J Dermatol.2002 Apr; 41(4): 220–4.
2.
ChandrakumarS.F.YeungJ.J.. Interleukin-17 antagonists in the treatment of psoriasis.J Cutan Med Surg.2015 Mar-Apr; 19(2): 109–14.
3.
GottliebA.B.LangleyR.G.PhilippS.Secukinumab Improves Physical Function in Subjects with Plaque Psoriasis and Psoriatic Arthritis: Results from Two Randomized, Phase 3 Trials.J Drugs Dermatol.2015 Aug; 14(8): 821–33.
4.
LowesM.A.KikuchiT.Fuentes-DuculanJ.Psoriasis Vulgaris Lesions Contain Discrete Populations of Th1 and Th17 T Cells.J Investigative Dermatol.2008 May; 128(5): 1207–211.
5.
Cosentyx [package insert].New Hanover, NJ: Novartis Pharmaceutifcal Corp; January 2015.
6.
ParkH.LiZ.YangX.A Distinct Lineage of CD4 T Cells Regulates Tissue Inflammation by Producing Interleukin 17.Nat Immunol.2005 Nov; 6(11): 1133–41.
7.
NijstenT.MargolisD.J.FeldmanS.R.RolstadT.SternR.S.. Traditional systemic treatments have not fully met the needs of psoriasis patients: results from a national survey.J Am Acad Dermatol.2005 Mar; 52(3 Pt 1): 434–44.
8.
CuchacovichR.Perez-AlaminoR.Garcia-ValladaresI.EspinozaL.R.. Steps in the Management of Psoriatic Arthritis: A Guide for Clinicians.Ther Adv Chronic Dis.2012 Nov; 3(6): 259–69.
9.
QuachO.L.HsuS.. Perianal Dermatophytosis During Secukinumab Therapy for Plaque Psoriasis.JAMA Dermatol.2016 Apr 1;152(4): 486–7.
10.
LangleyR.G.ElewskiB.E.LebwohlM.Secukinumab in Plaque Psoriasis – Results of Two Phase 3 Trials.NEJM.2014 Jul 24;371(4): 326–38.
11.
KrsticA.MojsilovicS.JovcicG.BugarskiD.. The Potential of Interleukin-17 to Mediate Hematopoietic Response.Immunol Research.2012 Apr; 52(1-2): 34–41.
12.
TorradoE.CooperA.M.. IL-17 and Th17 Cells in Tuberculosis.Cytokine Growth Factor Rev.2010 Dec; 21(6): 455–62.
13.
HueberW.SandsB.E.LewitzkyS.Secukinumab, a Human Anti-IL-17A Monoclonal Antibody, for Moderate to Severe Crohn's Disease: Unexpected Results of a Randomised, Double-blind Placebo-controlled Trial.Gut.2012 Dec; 61(12): 1693–700.
14.
LangleR.G.FeldmanS.R.NyiradyJ.van de KerkhofP.PapavassalisC.. The 5-point Investigator's Global Assessment (IGA) Scale: A Modified Tool for Evaluating Plaque Psoriasis Severity in Clinical Trials.J Dermatolog Treat.2015 Feb; 26(1): 23–31.
15.
WeismanS.PollackC.R.GottschalkR.W.. Psoriasis Disease Severity Measures: Comparing Efficacy of Treatments for Severe Psoriasis.J Dermatolog Treat.2003 Sep; 14(3): 158–65.
16.
HeD.LiH.YusufN.IL-17 Mediated Inflammation Promotes Tumor Growth and Progression in the Skin.PLoS One.2012; 7(2): e32126.
17.
LebwohlM.KavanaughA.ArmstrongA.W.Van VoorheesA.S.. US Perspectives in the Management of Psoriasis and Psoriatic Arthritis: Patient and Physician Results from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey.Am J Clin Dermatol.2016 Feb; 17(1): 87–97.
18.
LeonardiC.MathesonR.ZachariaeC.Anti-Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis.NEJM.2012 Mar 29;366(13): 1190–9.
19.
MeaseP.J.GenoveseM.C.GreenwaldM.W.Brodalumab, an Anti-IL17RA Monoclonal Antibody, in Psoriatic Arthritis.NEJM.2014 Jun 12;370(24): 2295–306.
20.
BlauveltA.PrinzJ.C.GottliebA.B.FEATURE Study Group, Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis.Br J Dermatol.2015; 172(2): 484–493.
21.
PaulC.LacourJ.P.TedremetsL.JUNCTURE study group, Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial.J Eur Acad Dermatol Venereol.2015; 29(6): 1082–1090.
22.
OhtsukiM.MoritaA.AbeM.Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study.J Dermatol.2014; 41(12): 1039–1046.
